# CtDNA for Early Response Assessment in PCNSL Treated with 1st Line Curative Intent (NLG-PCNSL-01)

> **NCT06755619** · — · RECRUITING · sponsor: **Nordic Lymphoma Group** · enrollment: 60 (estimated)

## Conditions studied

- Primary Central Nervous System (CNS) Lymphoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06755619
- **Lead sponsor:** Nordic Lymphoma Group
- **Sponsor class:** NETWORK
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-01
- **Primary completion:** 2030-12-31
- **Final completion:** 2038-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-01-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06755619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06755619, "CtDNA for Early Response Assessment in PCNSL Treated with 1st Line Curative Intent (NLG-PCNSL-01)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06755619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*